$TRUP
TRUPANION, INC. Stock $trup

$trup Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000137128523000146 Filed on May 05, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$270.6M	$256.3M	$246.0M
YoY Change	23.31%	24.43%	26.56%
Cost Of Revenue	$241.2M	$230.0M	$212.4M
YoY Change	26.39%	30.59%	29.61%
Gross Profit	$29.37M	$26.35M	$33.65M
YoY Change	2.76%	-11.87%	10.2%
Gross Profit Margin	10.86%	10.28%	13.68%
Selling, General & Admin	$33.91M	$42.66M	$33.03M
YoY Change	5.27%	37.64%	14.52%
% of Gross Profit	115.43%	161.92%	98.16%
Research & Development	$5.232M	$4.900M	$6.955M
YoY Change	-18.2%	-6.29%	49.09%
% of Gross Profit	17.81%	18.6%	20.67%
Depreciation & Amortization	$3.253M	$3.202M	$2.897M
YoY Change	20.17%	17.85%	4.58%
% of Gross Profit	11.07%	12.15%	8.61%
Operating Expenses	$42.39M	$50.76M	$42.88M
YoY Change	2.61%	30.36%	18.21%
Operating Profit	-$13.09M	-$24.49M	-$9.232M
YoY Change	2.5%	168.66%	60.81%
Interest Expense	$2.940M	$2.387M	-$1.672M
YoY Change	146.44%	2921.52%	5293.55%
% of Operating Profit
Other Income/Expense, Net	$2.078M	$1.902M	$1.504M
YoY Change	469.32%	505.73%	-737.29%
Pretax Income	-$13.95M	-$24.97M	-$9.300M
YoY Change	2.6%	181.24%	54.79%
Income Tax	-$238.0K	-$191.0K	-$15.00K
% Of Pretax Income
Net Earnings	-$13.71M	-$24.78M	-$9.285M
YoY Change	0.7%	179.84%	31.85%
Net Earnings / Revenue	-5.07%	-9.67%	-3.77%
Basic Earnings Per Share	-$0.33	-$0.60
Diluted Earnings Per Share	-$0.33	-$0.60	-$0.23
COMMON SHARES
Basic Shares Outstanding	41.23M shares	41.02M shares	40.88M shares
Diluted Shares Outstanding	41.38M shares	41.11M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$236.1M	$244.6M	$222.4M
YoY Change	-2.87%	-5.56%	4.22%
Cash & Equivalents	$118.4M	$126.7M	$65.61M
Short-Term Investments	$117.6M	$117.9M	$156.8M
Other Short-Term Assets	$18.88M	$17.49M	$14.25M
YoY Change	23.83%	20.73%	15.6%
Inventory
Prepaid Expenses
Receivables	$265.6M	$248.2M	$232.4M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$520.6M	$510.4M	$469.1M
YoY Change	12.55%	10.33%	19.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$97.98M	$94.47M	$90.70M
YoY Change	17.99%	17.55%	16.36%
Goodwill	$43.88M	$43.03M	$41.98M
YoY Change	49.22%	35.34%	28.35%
Intangibles	$21.63M	$23.02M	$24.03M
YoY Change	9.49%	8.0%	6.04%
Long-Term Investments	$9.818M	$8.440M	$300.0K
YoY Change	3172.67%	2713.33%	0.0%
Other Assets	$18.15M	$19.54M	$18.94M
YoY Change	-5.68%	10.28%	6.57%
Total Long-Term Assets	$209.6M	$207.6M	$202.5M
YoY Change	21.41%	20.63%	18.01%
TOTAL ASSETS
Total Short-Term Assets	$520.6M	$510.4M	$469.1M
Total Long-Term Assets	$209.6M	$207.6M	$202.5M
Total Assets	$730.2M	$717.9M	$671.6M
YoY Change	14.96%	13.13%	19.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.918M	$7.384M	$9.471M
YoY Change	6.81%	27.42%	5.8%
Accrued Expenses	$29.89M	$29.56M	$32.62M
YoY Change	-4.11%	-0.63%	15.82%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.100M	$1.263M	$1.103M
YoY Change	80.62%	107.39%
Total Short-Term Liabilities	$330.7M	$312.0M	$289.6M
YoY Change	27.08%	27.01%	29.47%
LONG-TERM LIABILITIES
Long-Term Debt	$102.9M	$102.9M	$68.35M
YoY Change	91.96%	91.82%
Other Long-Term Liabilities	$4.901M	$5.024M	$4.968M
YoY Change	18.87%	23.68%	28.74%
Total Long-Term Liabilities	$107.8M	$108.0M	$4.968M
YoY Change	86.74%	87.03%	28.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$330.7M	$312.0M	$289.6M
Total Long-Term Liabilities	$107.8M	$108.0M	$4.968M
Total Liabilities	$441.4M	$423.1M	$366.3M
YoY Change	37.77%	38.23%	59.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$210.1M	-$196.3M	-$171.6M
YoY Change	40.63%	44.64%	35.21%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$16.53M	$16.53M	$16.53M
YoY Change	0.02%	53.39%	53.39%
Treasury Stock Shares			1.028M shares
Shareholders Equity	$288.8M	$294.8M	$305.3M
YoY Change
Total Liabilities & Shareholders Equity	$730.2M	$717.9M	$671.6M
YoY Change	14.96%	13.13%	19.38%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$13.71M	-$24.78M	-$9.285M
YoY Change	0.7%	179.84%	31.85%
Depreciation, Depletion And Amortization	$3.253M	$3.202M	$2.897M
YoY Change	20.17%	17.85%	4.58%
Cash From Operating Activities	-$3.405M	-$6.862M	$1.019M
YoY Change	8.79%	91.14%	-80.24%
INVESTING ACTIVITIES
Capital Expenditures	$4.735M	$5.184M	$5.478M
YoY Change	-220.61%	45.9%	-243.48%
Acquisitions
YoY Change
Other Investing Activities	-$794.0K	-$100.0K	-$25.07M
YoY Change	-88.59%	-2100.0%	53.94%
Cash From Investing Activities	-$5.529M	$33.91M	-$30.55M
YoY Change	-49.21%	-337.98%	51.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-93.00K	$33.81M	14.68M
YoY Change	-98.45%	-35.92%	-3355.43%
NET CHANGE
Cash From Operating Activities	-3.405M	-$6.862M	1.019M
Cash From Investing Activities	-5.529M	$33.91M	-30.55M
Cash From Financing Activities	-93.00K	$33.81M	14.68M
Net Change In Cash	-9.027M	$61.12M	-14.85M
YoY Change	-54.89%	74.32%	-3.57%
FREE CASH FLOW
Cash From Operating Activities	-$3.405M	-$6.862M	$1.019M
Capital Expenditures	$4.735M	$5.184M	$5.478M
Free Cash Flow	-$8.140M	-$12.05M	-$4.459M
YoY Change	-1122.61%	68.64%	-149.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001371285
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36537
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	TRUPANION, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-0480694
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	6100 4th Avenue S, Suite 400
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Seattle,
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	98108
CY2023Q1	dei	City Area Code CityAreaCode	(855)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	727 - 9079
CY2023Q1	dei	Security12b Title Security12bTitle	Common stock, $0.00001 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	TRUP
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41225373	shares
CY2022Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	1000000	usd
CY2023Q1	us-gaap	Revenues Revenues	256329000	usd
CY2022Q1	us-gaap	Revenues Revenues	205999000	usd
CY2023Q1	trup	Claims Expense ClaimsExpense	194137000	usd
CY2022Q1	trup	Claims Expense ClaimsExpense	144926000	usd
CY2023Q1	trup	Other Costof Services Sold OtherCostofServicesSold	35846000	usd
CY2022Q1	trup	Other Costof Services Sold OtherCostofServicesSold	31179000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	229983000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	176105000	usd
CY2023Q1	trup	Technologyand Development Expense TechnologyandDevelopmentExpense	4900000	usd
CY2022Q1	trup	Technologyand Development Expense TechnologyandDevelopmentExpense	5229000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21017000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9366000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	21642000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	21627000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3202000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2717000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	50761000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	38939000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-71000	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-69000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24486000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9114000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	2387000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	79000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1902000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	314000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24971000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8879000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-191000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-24000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24780000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8855000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41107889	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41107889	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40581989	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40581989	shares
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24780000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8855000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1555000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-898000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	491000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2046000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-898000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22734000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9753000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126714000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65605000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	117910000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	156804000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	659000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	540000	usd
CY2023Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	248244000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	232439000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	17491000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	14248000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	510359000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	469096000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	19045000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	19032000	usd
CY2023Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	8440000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	7841000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	94472000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	90701000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23023000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24031000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	19544000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18943000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	43031000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	41983000	usd
CY2023Q1	us-gaap	Assets Assets	717914000	usd
CY2022Q4	us-gaap	Assets Assets	671627000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	7384000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9471000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	29560000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32616000	usd
CY2023Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	48295000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	43734000	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	225513000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	202692000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1263000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1103000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	312015000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	289616000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	102936000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	68354000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3130000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3392000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5024000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4968000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	423105000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	366330000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42355888	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41327702	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42041344	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41013158	shares
CY2023Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	511940000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	499694000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4255000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6301000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-196342000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171562000	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1028186	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1028186	shares
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	16534000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	16534000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	294809000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	305297000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	717914000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	671627000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	305297000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	713000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12959000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2046000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24780000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	294809000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	332200000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1699000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7785000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-898000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8855000	usd
CY2022Q1	trup	Increase Decreasein Claims Reserveand Loss Adjustment IncreaseDecreaseinClaimsReserveandLossAdjustment	-1213000	usd
CY2023Q1	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	22936000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	328533000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24780000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8855000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3202000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2717000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	12331000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7549000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	397000	usd
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	79000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15847000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23815000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3765000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2060000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5148000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1806000	usd
CY2023Q1	trup	Increase Decreasein Claims Reserveand Loss Adjustment IncreaseDecreaseinClaimsReserveandLossAdjustment	4606000	usd
CY2022Q1	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	23972000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6862000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3590000	usd
CY2023Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	34795000	usd
CY2022Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	22892000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	73793000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	12199000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5184000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3553000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-100000	usd
CY2022Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	5000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	33914000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14251000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	35130000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	54463000	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	607000	usd
CY2022Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	140000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	600000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	853000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2298000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	33810000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	52765000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	260000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	61122000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	35063000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84637000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100869000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	145759000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135932000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1243000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	945000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of Operations and Significant Accounting Policies<div style="margin-bottom:5pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business and Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the "Company") provides medical insurance for cats and dogs throughout the United States, Canada, Europe, Puerto Rico, and Australia. The Company's data-driven, vertically-integrated approach enables the Company to provide pet owners with products that the Company believes are the highest value medical insurance, priced specifically for each pet’s unique characteristics. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data as of December 31, 2022 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive income (loss), stockholders' equity and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) on February 16, 2023 (the 2022 10-K). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2022 10-K. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the full fiscal year or any other interim period.</span></div><div style="margin-bottom:5pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2022 10-K for additional discussion of these estimates and assumptions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts and Other Receivabl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es </span></div>Receivables are comprised of trade receivables and other miscellaneous receivables. Accounts and other receivables are carried at their estimated collectible amounts. Accounts receivable balance is primarily related to the Company’s other business segment where the Company generates revenue from underwriting policies through unaffiliated general agents. During the three months ended March 31, 2023, the Company incurred a non-recurring $3.8 million settlement of accounts receivable due to uncollected premiums in connection with the transition of underwriting a third-party business to other insurers.
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:5pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2022 10-K for additional discussion of these estimates and assumptions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts and Other Receivabl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es </span></div>Receivables are comprised of trade receivables and other miscellaneous receivables. Accounts and other receivables are carried at their estimated collectible amounts. Accounts receivable balance is primarily related to the Company’s other business segment where the Company generates revenue from underwriting policies through unaffiliated general agents. During the three months ended March 31, 2023, the Company incurred a non-recurring $3.8 million settlement of accounts receivable due to uncollected premiums in connection with the transition of underwriting a third-party business to other insurers.
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	3800000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	41983000	usd
CY2023Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	usd
CY2023Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	1048000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	43031000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	2755000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	2740000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	86104000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	86079000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost	88859000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	88819000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount	15996000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	15980000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	158000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	155000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities Single Maturity Date Amortized Cost Basis HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	16154000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities Single Maturity Date Fair Value HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue	16135000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	300000	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	0	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	24000000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	117273000	usd
CY2020Q4	trup	Purchaseof Equity Interest PurchaseofEquityInterest	7000000	usd
CY2023Q1	us-gaap	Financing Receivable Revolving FinancingReceivableRevolving	5600000	usd
CY2023Q1	us-gaap	Notes Receivable Net NotesReceivableNet	6500000	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	6300000	usd
CY2023Q1	trup	Servicesperformedfor Variable Interest Entity ServicesperformedforVariableInterestEntity	200000	usd
CY2022Q1	trup	Servicesperformedfor Variable Interest Entity ServicesperformedforVariableInterestEntity	200000	usd
CY2023Q1	us-gaap	Noncontrolling Interest In Variable Interest Entity NoncontrollingInterestInVariableInterestEntity	4115000	usd
CY2022Q4	us-gaap	Noncontrolling Interest In Variable Interest Entity NoncontrollingInterestInVariableInterestEntity	4115000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	113730000	usd
CY2022Q4	us-gaap	Noncontrolling Interest In Variable Interest Entity NoncontrollingInterestInVariableInterestEntity	4100000	usd
CY2023Q1	us-gaap	Noncontrolling Interest In Variable Interest Entity NoncontrollingInterestInVariableInterestEntity	4100000	usd
CY2023Q1	us-gaap	Notes Receivable Fair Value Disclosure NotesReceivableFairValueDisclosure	9500000	usd
CY2022Q4	us-gaap	Notes Receivable Fair Value Disclosure NotesReceivableFairValueDisclosure	9300000	usd
CY2023Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	150000000	usd
CY2023Q1	us-gaap	Line Of Credit Facility Initiation Date1 LineOfCreditFacilityInitiationDate1	2022-03-25
CY2023Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	150000000	usd
CY2023Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.1005
CY2023Q1	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	5900000	usd
CY2023Q1	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2027-03-25
CY2023Q1	trup	Line Of Credit Facility Periodic Payment Principal Percentage LineOfCreditFacilityPeriodicPaymentPrincipalPercentage	0.0025
CY2023Q1	us-gaap	Line Of Credit Facility Frequency Of Payments LineOfCreditFacilityFrequencyOfPayments	quarterly
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	988000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1100000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1100000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1100000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	71862000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	33250000	usd
CY2023Q1	us-gaap	Line Of Credit LineOfCredit	109400000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12331000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7549000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	628000	usd
CY2022Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	236000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	12959000	usd
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	7785000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	4800000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	629650	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.53
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	21410000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	13387	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.47
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	558000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	350	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	15.42
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	615913	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.59
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	18045000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	615913	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	13.59
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	18045000	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41327702	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	0	shares
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-71000	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-69000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24486000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9114000	usd
CY2023Q1	us-gaap	Revenues Revenues	256329000	usd
CY2022Q1	us-gaap	Revenues Revenues	205999000	usd
CY2023Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	800000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001371285-23-000146-index-headers.html	Edgar Link	pending
0001371285-23-000146-index.html	Edgar Link	pending
0001371285-23-000146.txt	Edgar Link	pending
0001371285-23-000146-xbrl.zip	Edgar Link	pending
ex311q12023.htm	Edgar Link	pending
ex312q12023.htm	Edgar Link	pending
ex321q12023.htm	Edgar Link	pending
ex322q12023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trup-20230331.htm	Edgar Link	pending
trup-20230331.xsd	Edgar Link	pending
trup-20230331_cal.xml	Edgar Link	unprocessable
trup-20230331_def.xml	Edgar Link	unprocessable
trup-20230331_pre.xml	Edgar Link	unprocessable
trup-20230331_lab.xml	Edgar Link	unprocessable
trup-20230331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TRUP
TRUPANION, INC. Stock $trup

2023 Q2 Form 10-Q Financial Statement

#000137128523000146 Filed on May 05, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRUP TRUPANION, INC. Stock $trup

2023 Q2 Form 10-Q Financial Statement

#000137128523000146 Filed on May 05, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRUP
TRUPANION, INC. Stock $trup